In a UK study, cost savings associated with SC versus IV trastuzumab have been estimated as £111.81 per patient episode, equating to a potential saving of £2012.58 per patient over a full course of adjuvant trastuzumab treatment for HER2-positive early breast cancer (Burcombe et al., 2013). The gene discussed is ERBB2; the disease is breast carcinoma.